Margot Zöller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Margot Zöller has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Mario Vitacolonna
Department of Tumor Progression and Tumor Defense, German Cancer Research Center, Heidelberg, Germany
6 shared publications- Rachid Marhaba
Department of Tumor Progression and Tumor Defense, German Cancer Research Center, Heidelberg, Germany
6 shared publications Siegfried Matzku
3 shared publicationsAndreas Claas
Departments of Tumor Progression and Tumor Defense, German Cancer Research Center, Heidelberg, Germany
2 shared publications- Annette Kopp-Schneider
Division of Biostatistics German Cancer Research Center (DKFZ) Heidelberg Germany
2 shared publications Axel Haferkamp
University Hospital of Urology , Heidelberg
2 shared publications
Latest Publications
- 1 January 2016
- Published by Springer Nature
- p. 3716-3720
Progression
- 20 November 2015
- Published by Springer Nature
- p. 1-5
Progression
- Open Access
- 15 July 2010
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 185 (2) , 902-916
Concomitant Tumor and Autoantigen Vaccination Supports Renal Cell Carcinoma Rejection
Efficient tumor vaccination frequently requires adjuvant. Concomitant induction of an autoimmune response is discussed as a means to strengthen a weak tumor Ag-specific response. We asked whether the efficacy of dendritic cell (DC) vaccination with the renal cell carcinoma Ags MAGE-A9 (MAGE9) and G250 could be strengthened by covaccination with the renal cell carcinoma autoantigen GOLGA4. BALB/c mice were vaccinated with DC loaded with MHC class I-binding peptides of MAGE9 or G250 or tumor lysate, which sufficed for rejection of low-dose RENCA-MAGE9 and RENCA-G250 tumor grafts, but only retarded tumor growth at 200 times the tumor dose at which 100% of animals will develop a tumor. Instead, 75–100% of mice prevaccinated concomitantly with Salmonella typhimurium transformed with GOLGA4 cDNA in a eukaryotic expression vector rejected 200 times the tumor dose at which 100% of animals will develop tumor. In a therapeutic setting, the survival rate increased from 20–40% by covaccination with S. typhimurium-GOLGA4. Autoantigen covaccination significantly strengthened tumor Ag-specific CD4+ and CD8+ T cell expansion, particularly in peptide-loaded DC-vaccinated mice. Covaccination was accompanied by an increase in inflammatory cytokines, boosted IL-12 and IFN-γ expression, and promoted a high tumor Ag-specific CTL response. Concomitant autoantigen vaccination also supported CCR6, CXCR3, and CXCR4 upregulation and T cell recruitment into the tumor. It did not affect regulatory T cells, but slightly increased myeloid-derived suppressor cells. Thus, tumor cell eradication was efficiently strengthened by concomitant induction of an immune response against a tumor Ag and an autoantigen expressed by the tumor cell. Activation of autoantigen-specific Th cells strongly supports tumor-specific Th cells and thereby CTL activation.
- 15 July 2010
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 185 (2) , 902-916
Open AccessConcomitant Tumor and Autoantigen Vaccination Supports Renal Cell Carcinoma Rejection
Efficient tumor vaccination frequently requires adjuvant. Concomitant induction of an autoimmune response is discussed as a means to strengthen a weak tumor Ag-specific response. We asked whether the efficacy of dendritic cell (DC) vaccination with the renal cell carcinoma Ags MAGE-A9 (MAGE9) and G250 could be strengthened by covaccination with the renal cell carcinoma autoantigen GOLGA4. BALB/c mice were vaccinated with DC loaded with MHC class I-binding peptides of MAGE9 or G250 or tumor lysate, which sufficed for rejection of low-dose RENCA-MAGE9 and RENCA-G250 tumor grafts, but only retarded tumor growth at 200 times the tumor dose at which 100% of animals will develop a tumor. Instead, 75–100% of mice prevaccinated concomitantly with Salmonella typhimurium transformed with GOLGA4 cDNA in a eukaryotic expression vector rejected 200 times the tumor dose at which 100% of animals will develop tumor. In a therapeutic setting, the survival rate increased from 20–40% by covaccination with S. typhimurium-GOLGA4. Autoantigen covaccination significantly strengthened tumor Ag-specific CD4+ and CD8+ T cell expansion, particularly in peptide-loaded DC-vaccinated mice. Covaccination was accompanied by an increase in inflammatory cytokines, boosted IL-12 and IFN-γ expression, and promoted a high tumor Ag-specific CTL response. Concomitant autoantigen vaccination also supported CCR6, CXCR3, and CXCR4 upregulation and T cell recruitment into the tumor. It did not affect regulatory T cells, but slightly increased myeloid-derived suppressor cells. Thus, tumor cell eradication was efficiently strengthened by concomitant induction of an immune response against a tumor Ag and an autoantigen expressed by the tumor cell. Activation of autoantigen-specific Th cells strongly supports tumor-specific Th cells and thereby CTL activation.
- Open Access
- 1 June 2010
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 14 (6b) , 1453-1467
Anti‐CD44 induces apoptosis in T lymphoma via mitochondrial depolarization
A blockade of CD44 can interfere with haematopoietic and leukemic stem cell homing, the latter being considered as a therapeutic option in haematological malignancies. We here aimed to explore the molecular mechanism underlying the therapeutic efficacy of anti‐CD44. We noted that in irradiated mice reconstituted with a bone marrow cell transplant, anti‐CD44 exerts a stronger effect on haematopoietic reconstitution than on T lymphoma (EL4) growth. Nonetheless, in the non‐reconstituted mouse anti‐CD44 suffices for a prolonged survival of EL4‐bearing mice, where anti‐CD44‐prohibited homing actively drives EL4 cells into apoptosis. In vitro, a CD44 occupancy results in a 2–4‐fold increase in apoptotic EL4 cells. Death receptor expression (CD95, TRAIL, TNFRI) remains unaltered and CD95 cross‐linking‐mediated apoptosis is not affected. Instead, CD44 ligation promotes mitochondrial depolarization that is accompanied by caspase‐9 cleavage and is inhibited in the presence of a caspase‐9 inhibitor. Apoptosis becomes initiated by activation of CD44‐associated phosphatase 2A (PP2A) and proceeds via ERK1/2 dephosphorylation without ERK1/2 degradation. Accordingly, CD44‐induced apoptosis could be mimicked by ERK1/2 inhibition, that also promotes EL4 cell apoptosis through the mitochondrial pathway. Thus, during haematopoietic stem cell reconstitution care should be taken not to interfere by a blockade of CD44 with haematopoiesis, which could be circumvented by selectively targeting leukemic CD44 isoforms. Beyond homing/settlement in the bone marrow niche, anti‐CD44 drives leukemic T cells into apoptosis via the mitochondrial death pathway by CD44 associating with PP2A. Uncovering this new pathway of CD44‐induced leukemic cell death provides new options of therapeutic interference.
- 1 June 2010
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 14 (6b) , 1453-1467
Open AccessAnti‐CD44 induces apoptosis in T lymphoma via mitochondrial depolarization
A blockade of CD44 can interfere with haematopoietic and leukemic stem cell homing, the latter being considered as a therapeutic option in haematological malignancies. We here aimed to explore the molecular mechanism underlying the therapeutic efficacy of anti‐CD44. We noted that in irradiated mice reconstituted with a bone marrow cell transplant, anti‐CD44 exerts a stronger effect on haematopoietic reconstitution than on T lymphoma (EL4) growth. Nonetheless, in the non‐reconstituted mouse anti‐CD44 suffices for a prolonged survival of EL4‐bearing mice, where anti‐CD44‐prohibited homing actively drives EL4 cells into apoptosis. In vitro, a CD44 occupancy results in a 2–4‐fold increase in apoptotic EL4 cells. Death receptor expression (CD95, TRAIL, TNFRI) remains unaltered and CD95 cross‐linking‐mediated apoptosis is not affected. Instead, CD44 ligation promotes mitochondrial depolarization that is accompanied by caspase‐9 cleavage and is inhibited in the presence of a caspase‐9 inhibitor. Apoptosis becomes initiated by activation of CD44‐associated phosphatase 2A (PP2A) and proceeds via ERK1/2 dephosphorylation without ERK1/2 degradation. Accordingly, CD44‐induced apoptosis could be mimicked by ERK1/2 inhibition, that also promotes EL4 cell apoptosis through the mitochondrial pathway. Thus, during haematopoietic stem cell reconstitution care should be taken not to interfere by a blockade of CD44 with haematopoiesis, which could be circumvented by selectively targeting leukemic CD44 isoforms. Beyond homing/settlement in the bone marrow niche, anti‐CD44 drives leukemic T cells into apoptosis via the mitochondrial death pathway by CD44 associating with PP2A. Uncovering this new pathway of CD44‐induced leukemic cell death provides new options of therapeutic interference.
- Open Access
- 17 March 2009
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 7 (3) , 285-299
Claudin-7 Regulates EpCAM-Mediated Functions in Tumor Progression
EpCAM has been described as a therapeutically relevant tumor marker. We noted an interaction between EpCAM and the tight junction protein claudin-7 and here explored the nature of this interaction and its effect on EpCAM-mediated functions. The interaction between EpCAM and claudin-7 was defined in HEK293 cells transfected with rat claudin-7 and EpCAM cDNA. Deletions of the epidermal growth factor–like and the thyroglobin repeat domains of EpCAM or the cytoplasmic domain of EpCAM or claudin-7 did not prevent the EpCAM-claudin-7 association. A chimeric EpCAM molecule with an exchange of the cytoplasmic and transmembrane domains and an EpCAM molecule with point mutations in an AxxxG motif in the transmembrane region do not associate with claudin-7. HEK cells and the rat pancreatic tumor line BSp73AS, transfected with (mutated) EpCAM and claudin-7 cDNA, revealed that the association of both molecules severely alters the functional activity of EpCAM. Claudin-7–associated EpCAM is recruited into tetraspanin-enriched membrane microdomains (TEM). The TEM-located claudin-7-EpCAM complex supports proliferation accompanied by sustained extracellular signal–regulated kinase-1/2 phosphorylation, up-regulation of antiapoptotic proteins, and drug resistance, but not EpCAM-mediated cell-cell adhesion. Enhanced motility may be supported by colocalization of claudin-7 with actin bundles, which is only seen in EpCAM-claudin-7–expressing cells. The EpCAM-claudin-7 complex strongly promotes tumorigenicity, accelerates tumor growth, and supports ascites production and thymic metastasis formation. High expression of the tumor marker EpCAM is frequently associated with poor prognosis, which could well rely on the EpCAM-claudin-7 association that prohibits EpCAM-mediated cell-cell adhesion but promotes migration, proliferation, apoptosis resistance, and tumorigenicity. (Mol Cancer Res 2009;7(3):285–99)
- 17 March 2009
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 7 (3) , 285-299
Open AccessClaudin-7 Regulates EpCAM-Mediated Functions in Tumor Progression
EpCAM has been described as a therapeutically relevant tumor marker. We noted an interaction between EpCAM and the tight junction protein claudin-7 and here explored the nature of this interaction and its effect on EpCAM-mediated functions. The interaction between EpCAM and claudin-7 was defined in HEK293 cells transfected with rat claudin-7 and EpCAM cDNA. Deletions of the epidermal growth factor–like and the thyroglobin repeat domains of EpCAM or the cytoplasmic domain of EpCAM or claudin-7 did not prevent the EpCAM-claudin-7 association. A chimeric EpCAM molecule with an exchange of the cytoplasmic and transmembrane domains and an EpCAM molecule with point mutations in an AxxxG motif in the transmembrane region do not associate with claudin-7. HEK cells and the rat pancreatic tumor line BSp73AS, transfected with (mutated) EpCAM and claudin-7 cDNA, revealed that the association of both molecules severely alters the functional activity of EpCAM. Claudin-7–associated EpCAM is recruited into tetraspanin-enriched membrane microdomains (TEM). The TEM-located claudin-7-EpCAM complex supports proliferation accompanied by sustained extracellular signal–regulated kinase-1/2 phosphorylation, up-regulation of antiapoptotic proteins, and drug resistance, but not EpCAM-mediated cell-cell adhesion. Enhanced motility may be supported by colocalization of claudin-7 with actin bundles, which is only seen in EpCAM-claudin-7–expressing cells. The EpCAM-claudin-7 complex strongly promotes tumorigenicity, accelerates tumor growth, and supports ascites production and thymic metastasis formation. High expression of the tumor marker EpCAM is frequently associated with poor prognosis, which could well rely on the EpCAM-claudin-7 association that prohibits EpCAM-mediated cell-cell adhesion but promotes migration, proliferation, apoptosis resistance, and tumorigenicity. (Mol Cancer Res 2009;7(3):285–99)
- Top Cited Papers
- 11 December 2008
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 9 (1) , 40-55
Tetraspanins: push and pull in suppressing and promoting metastasis
Tumours progress through a cascade of events that enable the formation of metastases. Some of the components that are required for this fatal process are well established. Tetraspanins, however, have only recently received attention as both metastasis suppressors and metastasis promoters. This late appreciation is probably due to their capacity to associate with various molecules, which they recruit into special membrane microdomains, and their abundant presence in tumour-derived small vesicles that aid intercellular communication. It is reasonable to assume that differences in the membrane and vesicular web components that associate with individual tetraspanins account for their differing abilities to promote and suppress metastasis.
- 11 December 2008
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 9 (1) , 40-55
Top Cited PapersTetraspanins: push and pull in suppressing and promoting metastasis
Tumours progress through a cascade of events that enable the formation of metastases. Some of the components that are required for this fatal process are well established. Tetraspanins, however, have only recently received attention as both metastasis suppressors and metastasis promoters. This late appreciation is probably due to their capacity to associate with various molecules, which they recruit into special membrane microdomains, and their abundant presence in tumour-derived small vesicles that aid intercellular communication. It is reasonable to assume that differences in the membrane and vesicular web components that associate with individual tetraspanins account for their differing abilities to promote and suppress metastasis.
- Open Access
- 24 April 2008
- Published by Wiley in International Journal of Cancer
- Vol. 123 (1) , 134-145
Opposing effects of fibrosarcoma cell‐derived IL‐1α and IL‐1β on immune response induction
There is evidence that cell‐associated IL‐1α supports immune response induction. Here we explored the impact of malignant cell‐derived IL‐1 on immunogenicity, immune response induction and tumor‐induced immunosuppression using 3‐methylcholanthrene‐induced fibrosarcoma lines derived from wild‐type (wt), IL‐1α‐, IL‐1β‐ or IL‐1aβ‐knockout (IL‐1α−/−, IL‐1β−/−, IL‐1αβ−/−) C57BL6 mice. The wt, IL‐1α−/−, IL‐1β−/− and IL‐1αβ−/− fibrosarcoma lines express MHC class I molecules at a high level. The lines do not differ in their susceptibility toward NK cells, macrophages, and allogeneic CTL, or in their capacity as stimulators of an allogeneic response. However, IL‐1β−/− tumors rarely grow in the syngeneic host, which is the consequence of a strong T helper and CTL response induction by IL‐1α‐competent, IL‐1β−/− tumors. On the other hand, IL‐1β‐competent, IL‐1α−/− tumors strongly assist CD11b+Gr‐1+ myeloid‐derived suppressor cell and regulatory T cell expansion, which both suppress with high efficacy activated T helper cell proliferation and CTL lysis. In IL‐1αβ−/− tumors, the absence of IL‐1α becomes decisive, i.e. despite reduced suppressor cell recruitment, tumor growth was unimpaired due to inefficient immune response induction. Thus, sarcoma cell‐derived IL‐1α and IL‐1β do not act in concert. Induction of a strong immune response by IL‐1α demands therapeutic exploitation, which may become more efficient if systemic induction of immunosuppression by IL‐1β can also be circumvented.
- 24 April 2008
- Published by Wiley in International Journal of Cancer
- Vol. 123 (1) , 134-145
Open AccessOpposing effects of fibrosarcoma cell‐derived IL‐1α and IL‐1β on immune response induction
There is evidence that cell‐associated IL‐1α supports immune response induction. Here we explored the impact of malignant cell‐derived IL‐1 on immunogenicity, immune response induction and tumor‐induced immunosuppression using 3‐methylcholanthrene‐induced fibrosarcoma lines derived from wild‐type (wt), IL‐1α‐, IL‐1β‐ or IL‐1aβ‐knockout (IL‐1α−/−, IL‐1β−/−, IL‐1αβ−/−) C57BL6 mice. The wt, IL‐1α−/−, IL‐1β−/− and IL‐1αβ−/− fibrosarcoma lines express MHC class I molecules at a high level. The lines do not differ in their susceptibility toward NK cells, macrophages, and allogeneic CTL, or in their capacity as stimulators of an allogeneic response. However, IL‐1β−/− tumors rarely grow in the syngeneic host, which is the consequence of a strong T helper and CTL response induction by IL‐1α‐competent, IL‐1β−/− tumors. On the other hand, IL‐1β‐competent, IL‐1α−/− tumors strongly assist CD11b+Gr‐1+ myeloid‐derived suppressor cell and regulatory T cell expansion, which both suppress with high efficacy activated T helper cell proliferation and CTL lysis. In IL‐1αβ−/− tumors, the absence of IL‐1α becomes decisive, i.e. despite reduced suppressor cell recruitment, tumor growth was unimpaired due to inefficient immune response induction. Thus, sarcoma cell‐derived IL‐1α and IL‐1β do not act in concert. Induction of a strong immune response by IL‐1α demands therapeutic exploitation, which may become more efficient if systemic induction of immunosuppression by IL‐1β can also be circumvented.
- 1 December 2007
- Published by Elsevier in Experimental Hematology
- Vol. 35 (12) , 1891-1905
Thymus repopulation after allogeneic reconstitution in hematological malignancies
- 1 December 2007
- Published by Elsevier in Experimental Hematology
- Vol. 35 (12) , 1891-1905
Thymus repopulation after allogeneic reconstitution in hematological malignancies
- Open Access
- 2 October 2007
- Published by Springer Nature in British Journal of Cancer
- Vol. 97 (8) , 1146-1156
C4.4A as a candidate marker in the diagnosis of colorectal cancer
C4.4A is a member of the Ly-6 family with restricted expression in non-transformed tissues. C4.4A expression in human cancer has rarely been evaluated. Thus, it became important to explore C4.4A protein expression in human tumour tissue to obtain an estimate on the frequency of expression and the correlation with tumour progression, the study focusing on colorectal cancer. The analysis of C4.4A in human tumour lines by western blot and immunoprecipitation using polyclonal rabbit antibodies that recognize different C4.4A epitopes revealed C4.4A oligomer and heavily glycosylated C4.4A isoform expression that, in some instances, inhibited antibody binding and interaction with the C4.4A ligand galectin-3. In addition, tumour cell lines released C4.4A by vesicle shedding and proteolytic cleavage. C4.4A was expressed in over 80% of primary colorectal cancer and liver metastasis with negligible expression in adjacent colonic mucosa, inflamed colonic tissue and liver. This compares well with EpCAM and CO-029 expression in over 90% of colorectal cancer. C4.4A expression was only observed in about 50% of pancreatic cancer and renal cell carcinoma. By de novo expression in colonic cancer tissue, we consider C4.4A as a candidate diagnostic marker in colorectal cancer, which possibly can be detected in body fluids.
- 2 October 2007
- Published by Springer Nature in British Journal of Cancer
- Vol. 97 (8) , 1146-1156
Open AccessC4.4A as a candidate marker in the diagnosis of colorectal cancer
C4.4A is a member of the Ly-6 family with restricted expression in non-transformed tissues. C4.4A expression in human cancer has rarely been evaluated. Thus, it became important to explore C4.4A protein expression in human tumour tissue to obtain an estimate on the frequency of expression and the correlation with tumour progression, the study focusing on colorectal cancer. The analysis of C4.4A in human tumour lines by western blot and immunoprecipitation using polyclonal rabbit antibodies that recognize different C4.4A epitopes revealed C4.4A oligomer and heavily glycosylated C4.4A isoform expression that, in some instances, inhibited antibody binding and interaction with the C4.4A ligand galectin-3. In addition, tumour cell lines released C4.4A by vesicle shedding and proteolytic cleavage. C4.4A was expressed in over 80% of primary colorectal cancer and liver metastasis with negligible expression in adjacent colonic mucosa, inflamed colonic tissue and liver. This compares well with EpCAM and CO-029 expression in over 90% of colorectal cancer. C4.4A expression was only observed in about 50% of pancreatic cancer and renal cell carcinoma. By de novo expression in colonic cancer tissue, we consider C4.4A as a candidate diagnostic marker in colorectal cancer, which possibly can be detected in body fluids.